Wednesday, 16 August 2017

Veristat acquires UK-based CRO Spero Oncology

03 May 2016 | News | By BioSpectrum Bureau

Veristat acquires UK-based CRO Spero Oncology

Veristat, a full service Clinical Research Organization (CRO), has announced that it is expanding its clinical research offerings into Europe through the acquisition of UK-based CRO, Spero Oncology.

Spero Oncology is a UK-based CRO specializing in providing clinical operations support for oncology clinical trials primarily throughout Europe, but also in Australia and New Zealand. With the acquisition of Spero Oncology, Veristat now offers its clients full clinical operations support in Europe including feasibility studies, legal representation in the European Union, Clinical Monitoring, Project Management, Protocol Writing and Regulatory Strategy.

"Veristat's expansion into Europe marks an important milestone in our history," stated Patrick Flanagan, Chief Executive Officer of Veristat. "Adding the Spero Oncology team to Veristat will strengthen our ability to deliver value to our clients' multi-national trials throughout North America and Europe. The Spero team has an impressive reputation for delivering valuable guidance and insight to their clients' clinical trials. We feel that this team is a great fit culturally and professionally and will enhance our ability to make a difference in the trials we perform on behalf of sponsors."

Spero Oncology will immediately be integrated and operate under the Veristat brand and name. Veristat has appointed Spero's Founder and Managing Director, Theresa Bruce, to the newly created position of Vice President of Clinical Operations at Veristat. In her new role, Theresa will provide leadership and strategic oversight to Veristat's global clinical operations team.

She joins Veristat with more than 23 years of clinical research experience in both the pharmaceutical and CRO industry. The release says that she is passionate about drug development having spent the last 16 years providing leadership and project management support for numerous oncology trials. Prior to founding Spero Oncology, she was the COO of Nexus Oncology. And, following the acquisition of Nexus by Ockham Oncology, she remained as Vice-President, Global Operations. Originally trained as a nurse, she worked as a Research Sister in a large teaching hospital in Glasgow and subsequently completed her MBA in the city.

"We are thrilled to be joining the Veristat family," stated Theresa Bruce, Vice President, Clinical Operations at Veristat. "Being part of an international CRO allows us to provide clients with an expanded service offering and the ability to run clinical trials in North America and Europe. Veristat is a great fit for my team because we share the same passion for helping clients bring new therapies to market."


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Does Asia have more to offer to the global 3D cell culture market?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls